Annual CFO
-$6.41 M
+$2.43 M+27.45%
December 1, 2023
Summary
- As of February 7, 2025, DRMA annual cash flow from operations is -$6.41 million, with the most recent change of +$2.43 million (+27.45%) on December 1, 2023.
- During the last 3 years, DRMA annual CFO has fallen by -$2.38 million (-59.09%).
- DRMA annual CFO is now -63.40% below its all-time high of -$3.92 million, reached on December 31, 2019.
Performance
DRMA Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$3.42 M
-$1.29 M-60.81%
September 1, 2024
Summary
- As of February 7, 2025, DRMA quarterly cash flow from operations is -$3.42 million, with the most recent change of -$1.29 million (-60.81%) on September 1, 2024.
- Over the past year, DRMA quarterly CFO has dropped by -$2.27 million (-198.00%).
- DRMA quarterly CFO is now -537.85% below its all-time high of -$536.00 thousand, reached on December 31, 2020.
Performance
DRMA Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$9.40 M
-$1.65 M-21.26%
September 1, 2024
Summary
- As of February 7, 2025, DRMA TTM cash flow from operations is -$9.40 million, with the most recent change of -$1.65 million (-21.26%) on September 1, 2024.
- Over the past year, DRMA TTM CFO has dropped by -$2.99 million (-46.62%).
- DRMA TTM CFO is now -581.36% below its all-time high of -$1.38 million, reached on March 31, 2020.
Performance
DRMA TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
DRMA Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +27.4% | -198.0% | -46.6% |
| 3 y3 years | -59.1% | -85.8% | -19.3% |
| 5 y5 years | -63.4% | -85.8% | -19.3% |
DRMA Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -12.6% | +27.4% | -198.0% | at low | -65.0% | at low |
| 5 y | 5-year | -63.4% | +27.4% | -537.9% | at low | -581.4% | at low |
| alltime | all time | -63.4% | +27.4% | -537.9% | at low | -581.4% | at low |
Dermata Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$3.42 M(+60.8%) | -$9.40 M(+21.3%) |
| Jun 2024 | - | -$2.13 M(-21.4%) | -$7.75 M(+3.8%) |
| Mar 2024 | - | -$2.70 M(+135.7%) | -$7.46 M(+16.5%) |
| Dec 2023 | -$6.41 M(-27.5%) | -$1.15 M(-35.2%) | -$6.41 M(-9.6%) |
| Sep 2023 | - | -$1.77 M(-3.7%) | -$7.09 M(-10.0%) |
| Jun 2023 | - | -$1.84 M(+11.6%) | -$7.88 M(+0.0%) |
| Mar 2023 | - | -$1.65 M(-9.6%) | -$7.88 M(-10.8%) |
| Dec 2022 | -$8.83 M | -$1.83 M(-28.7%) | -$8.83 M(+0.2%) |
| Sep 2022 | - | -$2.56 M(+39.2%) | -$8.81 M(+4.2%) |
| Jun 2022 | - | -$1.84 M(-29.5%) | -$8.46 M(+12.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | -$2.61 M(+44.6%) | -$7.52 M(+32.2%) |
| Dec 2021 | -$5.69 M(+41.3%) | -$1.80 M(-18.4%) | -$5.69 M(+28.7%) |
| Sep 2021 | - | -$2.21 M(+144.7%) | -$4.43 M(+23.4%) |
| Jun 2021 | - | -$903.20 K(+16.4%) | -$3.58 M(+4.7%) |
| Mar 2021 | - | -$776.20 K(+44.8%) | -$3.43 M(-15.0%) |
| Dec 2020 | -$4.03 M(+2.7%) | -$536.00 K(-60.9%) | -$4.03 M(+15.3%) |
| Sep 2020 | - | -$1.37 M(+84.1%) | -$3.49 M(+64.5%) |
| Jun 2020 | - | -$743.90 K(-46.1%) | -$2.12 M(+53.9%) |
| Mar 2020 | - | -$1.38 M | -$1.38 M |
| Dec 2019 | -$3.92 M | - | - |
FAQ
- What is Dermata Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Dermata Therapeutics?
- What is Dermata Therapeutics annual CFO year-on-year change?
- What is Dermata Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Dermata Therapeutics?
- What is Dermata Therapeutics quarterly CFO year-on-year change?
- What is Dermata Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Dermata Therapeutics?
- What is Dermata Therapeutics TTM CFO year-on-year change?
What is Dermata Therapeutics annual cash flow from operations?
The current annual CFO of DRMA is -$6.41 M
What is the all time high annual CFO for Dermata Therapeutics?
Dermata Therapeutics all-time high annual cash flow from operations is -$3.92 M
What is Dermata Therapeutics annual CFO year-on-year change?
Over the past year, DRMA annual cash flow from operations has changed by +$2.43 M (+27.45%)
What is Dermata Therapeutics quarterly cash flow from operations?
The current quarterly CFO of DRMA is -$3.42 M
What is the all time high quarterly CFO for Dermata Therapeutics?
Dermata Therapeutics all-time high quarterly cash flow from operations is -$536.00 K
What is Dermata Therapeutics quarterly CFO year-on-year change?
Over the past year, DRMA quarterly cash flow from operations has changed by -$2.27 M (-198.00%)
What is Dermata Therapeutics TTM cash flow from operations?
The current TTM CFO of DRMA is -$9.40 M
What is the all time high TTM CFO for Dermata Therapeutics?
Dermata Therapeutics all-time high TTM cash flow from operations is -$1.38 M
What is Dermata Therapeutics TTM CFO year-on-year change?
Over the past year, DRMA TTM cash flow from operations has changed by -$2.99 M (-46.62%)